Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by MrMugsyon Jul 05, 2022 11:28pm
84 Views
Post# 34804042

RE:Stutters

RE:Stutters
Forestview wrote: So, you make a comment that Paradigm doesn't own Antibe yet gives it a Buy rating.  But, if they did own it, which they would have to disclose, you'd accuse it of....let me guess, pumping. You and your weird cronies continuously harp on Mugs for that very same thing.  But, now you want a pumper?

To the investing world, you'd want to see an organization have no conflict of interest when making a rating, that's what give it credibility.    

Your idiocy and hypocrisy really knows no bounds.  It's quite astounding.  Good thing everyone has already painted you with that brush.  


You got your hands full with that sap Forestview - best to put his tush on ignore.

You'd likely have a better conversation wtih my grandmother who had Alzheimer's ... before she went 6 feet under.  God rest her soul ! 

hahaha !

-------------------------


<< Previous
Bullboard Posts
Next >>